e-learning
resources
European Respiratory Review
2012
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis
Richeldi Luca
Source:
Eur Respir Rev 2012; 21: 147-151
Journal Issue:
June 2012 - 21 (124)
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Richeldi Luca. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis. Eur Respir Rev 2012; 21: 147-151
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Emerging classes of drugs for the treatment of obstructive lung disease
Eosinophils and airway nerves in asthma
Related content which might interest you:
Evidence-based treatment strategies in idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2013; 22: 163-168
Year: 2013
The clinical efficacy of pulmonary hypertension-specific agents in idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study
Source: Eur Respir Rev 2008; 17: 116-122
Year: 2008
Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
Source: Eur Respir Rev, 29 (157) 190158; 10.1183/16000617.0158-2019
Year: 2020
Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF)
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment I
Year: 2016
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry
Source: International Congress 2015 – IPF: clinical aspects II
Year: 2015
A comparison of pirfenidone versus nintedanib for the management of idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety
Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms
Year: 2009
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
Source: ERJ Open Res, 7 (3) 00321-2021; 10.1183/23120541.00321-2021
Year: 2021
Assessing the effectiveness of pirfenidone in changing the natural course of idiopathic pulmonary fibrosis: the data from European IPF Registry (eurIPFreg).
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Pirfenidone post-authorization safety registry (PASSPORT) update
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Japanese guideline for the treatment of idiopathic pulmonary fibrosis 2017
Source: International Congress 2017 – IPF: from the bench to the bedside
Year: 2017
Does delay in review of newly-diagnosed idiopathic pulmonary fibrosis (IPF) worsen outcomes?
Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept